Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus BerdejaПодробнее

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus Berdeja

MCRT San Diego 2020: Jesús Berdeja Presentation - ImmunotherapiesПодробнее

MCRT San Diego 2020: Jesús Berdeja Presentation - Immunotherapies

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

The promise of belantamab mafodotin for the treatment of multiple myeloma

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

All About BLENREP (Belantamab Mafodotin-blmf)

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple Myeloma

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaПодробнее

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

DREAMM-2: Belantamab mafodotin for R/R myelomaПодробнее

DREAMM-2: Belantamab mafodotin for R/R myeloma

Treatment combinations being explored with belantamab mafodotin in multiple myelomaПодробнее

Treatment combinations being explored with belantamab mafodotin in multiple myeloma

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myeloma

Dr. Berdeja on Updated Data With bb21217 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma

Dr. Berdeja on Treatment of Patients With Newly Diagnosed MyelomaПодробнее

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

Belantamab Mafodotin for Multiple Myeloma | NEJMПодробнее

Belantamab Mafodotin for Multiple Myeloma | NEJM

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patientsПодробнее

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patients

Managing belantamab mafodotin-associated corneal adverse events in multiple myelomaПодробнее

Managing belantamab mafodotin-associated corneal adverse events in multiple myeloma

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials